Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Gazprom may take part in the construction of a gas hub in Iran

10/13/23 GAZP

UK regulator approves Microsoft's deal with Activision Blizzard

10/13/23 MSFT

UK regulator approves Microsoft's deal with Activision Blizzard

10/13/23 ATVI

Samolet Plus acquired the real estate agency Megapolis Service

10/13/23 SMLT

Acron's 9 months results increased marketable products output by 1.2%

10/13/23 AKRN

Ozon launched the largest fullfillment center in Khabarovsk

10/13/23 OZON

Astra IPO was at the upper end of the price range

10/13/23 ASTR

Seligdar increased capacity of the Ryabinovy complex factory by 6.25%

10/13/23 SELG

M.Video-Eldorado marketplace tests direct delivery of goods from CIS countries

10/13/23 MVID

Cosmos Hotel Group will deal with VIP-tourism

10/13/23 AFKS